Advanced medicine offers exciting new treatment options for patients in Australia. To ensure that patients can access these medications, however, the nation needs trusted and transparent regulatory frameworks. GAfPA’s advocates in Australia work to educate policymakers and fellow advocates about the importance of effective policy and patient safety.
Sophisticated biologic medicines present Australia with many of the same challenges that other nations face: naming conventions, indication extrapolation and the rules of substitution. Australia was a forerunner in creating a distinct naming system for biosimilar medications but had to reconsider its approach when the World Health Organization proposed its own recommendations. As Australia refines its regulatory approach to innovative medicine, GAfPA serves as an educational resource and advocate for patient-centered policy.